Kim et al. [13] proposed a two-step strategy for the use of immunostaining in renal cell carcinoma subtype diagnosis: first with the triple panel described above (CK7, AMACR and CAIX) and then, if necessary, with others markers like c-kit, CD10 or cathepsin-K. This evidence concerns the gene KRT7 and renal cell carcinoma.